About Opus Bio

About company

Opus Bio is a developer of lentiviral gene delivery products for therapeutic, vaccine and bioproduction applications. The company develops lentiviral vectors technology platform for delivery of genetic sequence information into cells to reprogram their function and it is applicable across epithelial cancers, including colon, small-cell lung, ovarian, breast cancer, stomach, esophageal, and others. Its product candidates include T-cell chimeric antigen receptor cellular therapy targeting CD22 for hematological malignancies.